drugset / Trial / NCT02370550
Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this large multicenter, randomized, double-blinded, controlled clinical study is to investigate the efficacy and safety of Cyclosporin A for primary Sjogren's syndrome associated pneumonitis(pSS-IP), which has important implications for the establishment of standardized diagnosis and treatment of pSS-IP.
Timeline
- Start
- 2015-03
- Primary completion
- 2021-03
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | — | Oral |
| Background | Calcium carbonate D | Unknown | 600 mg | Oral |
| Background | Prednisone | Other / unclassified | — | Oral |